Abstract:Cancer remains a major global cause of death, posing significant treatment challenges. The interactions between tumor cells and the tumor microenvironment (TME) are crucial in influencing tumor initiation, progression, metastasis, and treatment response. There has been significant research and clinical interest in targeting the TME as a therapeutic approach in cancer, with advancements being made through drug development. Histamine binds to HRH1 receptors on the TME, which inhibit CD8+ T cell activity, promote tumor growth, and contribute to resistance against immunotherapy. By inhibiting CD8+ T cells, the effectiveness of immunotherapies targeting these cells is reduced. By blocking the HRH1 pathway, H1-antihistamines can mitigate this suppression and enhance the response to immunotherapies that target CD8+ T cells. Therefore, understanding the role of histamine and its potential impact on T cells and the role of H1-antihistamines in improving immune-oncology (I/O) agents' efficacy ultimately could lead to more effective cancer therapies. The objective of this review is to examine the current literature to investigate the potential role of H1-antihistamines on the effectiveness of I/O drugs and their role in enhancing treatment against cancer. We conducted a comprehensive literature search, which included multiple databases including PubMed, Google Scholar, and EMBASE, as well as a search of oncology congresses. Our literature review initially identified thirty studies. Twenty-three of these were excluded for failing to meet inclusion criteria, which varied from study design to the type of antihistamines and patient populations involved. The clinical studies investigated the effect of different generations of H1-antihistamines in combination with I/O treatments on patients' outcomes. The findings from these studies indicated that patients using H1-antihistamines concomitantly with I/O agents experienced longer median overall survival (mOS), progression-free survival (mPFS), or improved survival compared to those who did not use antihistamines. Additionally, these trials differentiated between cationic and non-cationic H1-antihistamines, revealing that users of cationic antihistamines had overall better outcomes in terms of longer mOS and mPFS. The assessed trials were consistent in their comparisons of quantitative and qualitative, efficacy, and safety outcomes. Checkpoint inhibitors represent a significant breakthrough in cancer treatment; however, only 20-40% of patients respond to immunotherapies due to many factors, among them the highly immunosuppressive conditions of the TME in some cancer types. H1-antihistamines have been shown to potentiate the activity of immunotherapy by enhancing T cell activation in the TME. We reviewed the role of H1-antihistamines on clinical activity of immuno-oncology agents and integrated key clinical studies into a comprehensive resource for the first time, offering invaluable insights for future research. Drawing from our extensive experience in immuno-oncology clinical trials, the manuscript also provides practical recommendations for future research and therapeutic strategies to be implemented effectively.

Antihistamines for cancer immunotherapy: More than just treating allergies

The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1

Allergic Mediator Histamine Confers Immunotherapy Resistance in Cancer Patients via Histamine Receptor 1 on Macrophage

Enhancing immuno-oncology efficacy with H1-antihistamine in cancer therapy: a review of current research and findings

Rearch Progress on the Relationship Between Mast Cells and Cancer

H2 antihistamines: May be useful for combination therapies in cancer?

Histamine-related genes participate in the establishment of an immunosuppressive microenvironment and impact the immunotherapy response in hepatocellular carcinoma

Cetirizine Platinum(iv) Complexes with Antihistamine Properties Inhibit Tumor Metastasis by Suppressing Angiogenesis and Boosting Immunity

[Effect of Histamine on Metastasis of Melanoma B16 Cell Xenograft in C57BL/6 Mice].

IL-17 Producing Mast Cells Promote the Expansion of Myeloid-Derived Suppressor Cells in a Mouse Allergy Model of Colorectal Cancer

Natural killer cells contribute to 'hot' tumor regression in the allergic inflammatory environment

Bi - Directional Regulation of Histamine in Tumor Immunity

PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy

Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events

MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy

The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy

Chemokines and Chemokine Receptors Required for Optimal Responses to Anticancer Chemotherapy.

Regulatory cells and the effect of cancer immunotherapy

Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets

Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors

Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors